DOCSLIB.ORG

Abstract Book

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Abstract Book 11-14 September ABSTRACT BOOK www.wcpm2019.org 11-14 September ABSTRACT BOOK SPEAKERS Abstracts 11-14 September S1 - PITFALLS IN DIAGNOSIS AND TREATMENT FOR ADHERENT PLACENTA Yalinkaya A. Dicle University Medical Faculty Department of Obstetrics and Gynecology, Diyarbakir Definition Patients with adherent placenta (AP) have many pitfalls in obstetrics. Adherent Placenta, including placenta accreta, placenta increta and percreta, occurs as a result of placental villi penetrating the myometrium through a defect in the decidua basalis. Adherent placenta cases consist of placenta accreta ~75-78%, placenta accreta ~15-18% and placentae percreta ~5-7%. The incidence of Adherent Placenta (AP) was found 1 in 172 in 2016 and tends to increase continuously in parallel to cesarean section. Pitfalls in Adherent Placenta The patients with adherent placenta carry many life-threatening risks. Sudden massive hemorrhage, patient neglect, patient being away from the operation center or transferred in the critical situation, difficulty in transport, inadequate surgical team and medical facilities, inadequate blood and blood products support and undiagnosed cases are the main traps in the adherent placenta. Diagnosis The accurate diagnosis of adherent placenta depends on the following conditions: Determination of risk factors, the experience of the sonographer who examined the patient and the quality of the device used, such as 2D, 3D or real time 3D (4D) sonography. In addition, examination methods such as TVS, TAS or Color Doppler sonography are important in the diagnosis. The diagnosis of adherent placenta can be made by transvaginal sonography after detection of gestational sac at the beginning of pregnancy and definitive diagnosis can be made until 12 week of gestation. Recurrent cesarean section, myomectomy, endometrial damage, uterine artery embolization, maternal age, multiparity and uterine surgery are major risk factors for adherent placenta. What to do in case of emergency? Great vessel access, fluid replacement should be started, blood and blood products must be provided. If there is massive vaginal bleeding, balloon tamponade should be applied. If the facilities are insufficient, surgery should not be performed and patient should be transferred under optimal conditions possible. If AP is not diagnosed before cesarean section, the surgeon should request help from an experienced surgeon immediately. Relaparotomy should not be performed by the same surgeon without the help of an experienced surgeon. Treatment (Surgical Approach) AP is a potentially life-threatening obstetric condition that requires a multidisciplinary approach to be managed. If the patients with AP are followed and treated by experienced surgeons in multidisciplinary tertiary centers, the maternal morbidity and mortality can be reduced. AP surgery is performed in two ways such as radical and conservative (complete and partial). These patients should be operated by an experienced team in appropriate centers. 4 11-14 September Our Recommendations: • Adherent placenta should be diagnosed in the first trimester. • All patients who have undergone uterine surgery should be evaluated for adherent placenta. • AP patients should be examined at least once by an experienced specialist. • AP patients should not be away from the operation center. • Operations should be done in appropriate centers. • Operations should be performed by an experienced team. • Complete conservative surgery should be the first option in all patients. S2 - PRENATAL AND POSTNATAL CONSEQUENCES OF FETAL STRESS Salihagic Kadic A. University of Zagreb Medical School, Department of Physiology, Zagreb, Croatia Fetal development and growth are influenced by the intrauterine environment. A large number of factors can alter the intrauterine environment and lead to fetal stress. Maternal undernutrition or placental insufficiency and intrauterine growth restriction, maternal emotional stress or stressful life events, as well as fetal pain may trigger the stress response of the fetus. The neuroendocrine stress axis operates in the fetus from midgestation and includes the production and secretion of the corticotropin releasing hormone, adrenocorticotropic hormone and cortisol. Fetal glucocorticoid overexposure affects neurodevelopment, as well as the development of many organs and organ systems, and has lifelong consequences. In response to an adverse intrauterine conditions and prenatal stress, the fetus is able to adapt its physiology to promote survival. However, this adaptation can result in permanent changes in tissue and organ structure and function as well as metabolic changes. It has been shown that the underlying etiology of some of the most common diseases of the modern society, such as hypertension, obesity, diabetes and coronary heart disease, has been traced in intrauterine environment. Further, there is experimental evidence that increased maternal care and environmental enrichment can compensate for prenatal stress-induced effects. Recent data have also indicated gender differences in vulnerability to prenatal stress. Finally, stress-free intrauterine environment is crucial for normal prenatal and postnatal growth and development, as well as good health later in life. 5 11-14 September S3 - FETAL CRANIUM AND FACE AT 13 WEEKS SCAN Ebrashy A. Cairo Egypt Designates the description of the embryonic anatomy, the normal anatomic relations and the development of abnormalities as visualized by ultrasound To confirm the presence of normal anatomy or to make the diagnosis of an anomaly, we need knowledge of the normal embryonic development, including the appearance of the normal embryo. Embryo = to grow (Greek) up to 9 weeks Fetus =off spring in Latin from 9 weeks there after The anterior part of the neural tube expands to form the brain The neural tube goes on to form all parts of the brain The structural organization of the brain: the barin begins as a hollow tube and remains hollow 5 regions of the brain are formed during development The cavities of the brain are the ventricles At the Eighth week (7weeks0d-7wks-6d ) Embryo external form : The embryonic body appears as a triangle in the sagittal section. The embryonic body is slender in the coronal plane. The limbs are short, paddle-shaped outgrowths CNS: The relatively broad and shallow rhombencephalic cavity is always visible from 7 weeks onwards. It then has a well-defined rhombic shape in the cranial pole of the embryo. At the Ninth week (8wks0d-8wks6d) CRL=15-22mm CNS:The brain cavities are easily seen as large ‘holes’ in the embryonic head. No falx cerebri or choriod plexus at least in the first half In sagittal planes the forebrain vesicles ( telencephalic ,diencephalic, metencephalic) are seen. Limbs: both upper and lower buds are clearly seen at this stage At the Tenth week (9wks0d-9wks6d) Brain: CNS The hall mark of the 10th week is the Falx and the echogenic choroid plexus Mid sagittal plane depicts tortous ventricular system Telencephalic vesicle leading to Diencephalon followed by the cephalic flexure between the Diencephalon and the meten cephalon (cerebellum) then the myelencephalon (medulla oblongata and finally the rhombencephalon (hindbrain At the 12th week (11wk0d-11wk-6d)on words till the 14th week (13wk0d-13wk-6d ) CRL= 54-87mm .The ventricular system is obvious, cerebellum, cisterna magna (the posterior fossa) are seen. At this time the vermis is not completely closed. The complete development of the cerebellum will be completed at 17 weeks gestation What is the clinical application? Cavities appearing in the brain are mirror image to the embryological development of the CNS and allowed us to better understand sequential stages in development We can jude on cranium intactness, proper cleavage cleavage of the forebrain with the appearance of the falx as well as looking at the development of the posterior fossa to diagnose open spina bifida Check list for the cranium should include: 6 11-14 September Intact cranium Falx cerebrai Choroid plexus filling the ventricles: butterfly appearance How comment on the posterior fossa Double line in tilted axial plane Intracranial translucency in mid sagittal view What are the cranial anomalies that coud be diagnosed at this age Anencephaly Holoprosencephaly What are the potentials for the diagnosis of open spina bifida based on the cranial sequel of open spina bifuda In all cases of OSB 1-a thickening of the brain stem, a shortening of the distance between brain stem and occipital bone, and an increase in the ratio of brain stem diameter to BSOB distance to greater than 1 are observed. 2-When the tilted axial plane is used and the “single line” sign is observed, this represents the sonographic cluster of early first trimester diagnosis of OSB face at 13 week scan 1- Retronasal traiangle 2- Mandibular gap 3- Maxillary gap Conclusion Sonoembryology paved the way for more understanding of the embryological stages of the fetal organs including the CNS.Brain vesicles and ventricles embryological stages of development can be appreciated like mirror images in early TVS.It helped a lot in better understanding and following up this important stage of evolution to the full sized brain By 11-13 weeks we are able now to document integrity of the cranium as well as proper cleavage of the fore brain .This enabled us to diagnosis anomalies involving these parts e.g. anencephaly and holoprosencephaly The dynamic growth of the brain limits the full diagnosis of abnormalities involving these areas specially the
Load more

Recommended publications
  • Genetic Syndromes with an Increased Risk of Developing Cancer As an Example of the Use of New Technologies
    Genetics and Molecular Biology, 37, 1 (suppl), 241-249 (2014) Copyright © 2014, Sociedade Brasileira de Genética. Printed in Brazil www.sbg.org.br Review Article Impact of NGS in the medical sciences: Genetic syndromes with an increased risk of developing cancer as an example of the use of new technologies Pablo Lapunzina1,2, Rocío Ortiz López3,4, Lara Rodríguez-Laguna2, Purificación García-Miguel5, Augusto Rojas Martínez3,4 and Víctor Martínez-Glez1,2 1Centro de Investigación Biomédica en Red de Enfermedades Raras, Instituto de Salud Carlos III, Madrid, Spain. 2Instituto de Genética Médica y Molecular, Hospital Universitario la Paz, Madrid, Spain. 3Departamento de Bioquímica y Medicina Molecular, Facultad de Medicina, Universidad Autónoma de Nuevo León. Monterrey, Nuevo León, México. 4Centro de Investigación y Desarrollo en Ciencias de la Salud, Universidad Autónoma de Nuevo León, Monterrey, Nuevo León, México. 5Unidad de Oncología Pediátrica, Hospital Infantil La Paz, Madrid, Spain. Abstract The increased speed and decreasing cost of sequencing, along with an understanding of the clinical relevance of emerging information for patient management, has led to an explosion of potential applications in healthcare. Cur- rently, SNP arrays and Next-Generation Sequencing (NGS) technologies are relatively new techniques used to scan genomes for gains and losses, losses of heterozygosity (LOH), SNPs, and indel variants as well as to perform com- plete sequencing of a panel of candidate genes, the entire exome (whole exome sequencing) or even the whole ge- nome. As a result, these new high-throughput technologies have facilitated progress in the understanding and diagnosis of genetic syndromes and cancers, two disorders traditionally considered to be separate diseases but that can share causal genetic alterations in a group of developmental disorders associated with congenital malformations and cancer risk.
    [Show full text]
  • Megalencephaly and Macrocephaly
    277 Megalencephaly and Macrocephaly KellenD.Winden,MD,PhD1 Christopher J. Yuskaitis, MD, PhD1 Annapurna Poduri, MD, MPH2 1 Department of Neurology, Boston Children’s Hospital, Boston, Address for correspondence Annapurna Poduri, Epilepsy Genetics Massachusetts Program, Division of Epilepsy and Clinical Electrophysiology, 2 Epilepsy Genetics Program, Division of Epilepsy and Clinical Department of Neurology, Fegan 9, Boston Children’s Hospital, 300 Electrophysiology, Department of Neurology, Boston Children’s Longwood Avenue, Boston, MA 02115 Hospital, Boston, Massachusetts (e-mail: [email protected]). Semin Neurol 2015;35:277–287. Abstract Megalencephaly is a developmental disorder characterized by brain overgrowth secondary to increased size and/or numbers of neurons and glia. These disorders can be divided into metabolic and developmental categories based on their molecular etiologies. Metabolic megalencephalies are mostly caused by genetic defects in cellular metabolism, whereas developmental megalencephalies have recently been shown to be caused by alterations in signaling pathways that regulate neuronal replication, growth, and migration. These disorders often lead to epilepsy, developmental disabilities, and Keywords behavioral problems; specific disorders have associations with overgrowth or abnor- ► megalencephaly malities in other tissues. The molecular underpinnings of many of these disorders are ► hemimegalencephaly now understood, providing insight into how dysregulation of critical pathways leads to ►
    [Show full text]
  • WES Gene Package Multiple Congenital Anomalie.Xlsx
    Whole Exome Sequencing Gene package Multiple congenital anomalie, version 5, 1‐2‐2018 Technical information DNA was enriched using Agilent SureSelect Clinical Research Exome V2 capture and paired‐end sequenced on the Illumina platform (outsourced). The aim is to obtain 8.1 Giga base pairs per exome with a mapped fraction of 0.99. The average coverage of the exome is ~50x. Duplicate reads are excluded. Data are demultiplexed with bcl2fastq Conversion Software from Illumina. Reads are mapped to the genome using the BWA‐MEM algorithm (reference: http://bio‐bwa.sourceforge.net/). Variant detection is performed by the Genome Analysis Toolkit HaplotypeCaller (reference: http://www.broadinstitute.org/gatk/). The detected variants are filtered and annotated with Cartagenia software and classified with Alamut Visual. It is not excluded that pathogenic mutations are being missed using this technology. At this moment, there is not enough information about the sensitivity of this technique with respect to the detection of deletions and duplications of more than 5 nucleotides and of somatic mosaic mutations (all types of sequence changes). HGNC approved Phenotype description including OMIM phenotype ID(s) OMIM median depth % covered % covered % covered gene symbol gene ID >10x >20x >30x A4GALT [Blood group, P1Pk system, P(2) phenotype], 111400 607922 101 100 100 99 [Blood group, P1Pk system, p phenotype], 111400 NOR polyagglutination syndrome, 111400 AAAS Achalasia‐addisonianism‐alacrimia syndrome, 231550 605378 73 100 100 100 AAGAB Keratoderma, palmoplantar,
    [Show full text]
  • Mackenzie's Mission Gene & Condition List
    Mackenzie’s Mission Gene & Condition List What conditions are being screened for in Mackenzie’s Mission? Genetic carrier screening offered through this research study has been carefully developed. It is focused on providing people with information about their chance of having children with a severe genetic condition occurring in childhood. The screening is designed to provide genetic information that is relevant and useful, and to minimise uncertain and unclear information. How the conditions and genes are selected The Mackenzie’s Mission reproductive genetic carrier screen currently includes approximately 1300 genes which are associated with about 750 conditions. The reason there are fewer conditions than genes is that some genetic conditions can be caused by changes in more than one gene. The gene list is reviewed regularly. To select the conditions and genes to be screened, a committee comprised of experts in genetics and screening was established including: clinical geneticists, genetic scientists, a genetic pathologist, genetic counsellors, an ethicist and a parent of a child with a genetic condition. The following criteria were developed and are used to select the genes to be included: • Screening the gene is technically possible using currently available technology • The gene is known to cause a genetic condition • The condition affects people in childhood • The condition has a serious impact on a person’s quality of life and/or is life-limiting o For many of the conditions there is no treatment or the treatment is very burdensome for the child and their family. For some conditions very early diagnosis and treatment can make a difference for the child.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE Et Al
    US 20160281 166A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0281166 A1 BHATTACHARJEE et al. (43) Pub. Date: Sep. 29, 2016 (54) METHODS AND SYSTEMIS FOR SCREENING Publication Classification DISEASES IN SUBJECTS (51) Int. Cl. (71) Applicant: PARABASE GENOMICS, INC., CI2O I/68 (2006.01) Boston, MA (US) C40B 30/02 (2006.01) (72) Inventors: Arindam BHATTACHARJEE, G06F 9/22 (2006.01) Andover, MA (US); Tanya (52) U.S. Cl. SOKOLSKY, Cambridge, MA (US); CPC ............. CI2O 1/6883 (2013.01); G06F 19/22 Edwin NAYLOR, Mt. Pleasant, SC (2013.01); C40B 30/02 (2013.01); C12O (US); Richard B. PARAD, Newton, 2600/156 (2013.01); C12O 2600/158 MA (US); Evan MAUCELI, (2013.01) Roslindale, MA (US) (21) Appl. No.: 15/078,579 (57) ABSTRACT (22) Filed: Mar. 23, 2016 Related U.S. Application Data The present disclosure provides systems, devices, and meth (60) Provisional application No. 62/136,836, filed on Mar. ods for a fast-turnaround, minimally invasive, and/or cost 23, 2015, provisional application No. 62/137,745, effective assay for Screening diseases, such as genetic dis filed on Mar. 24, 2015. orders and/or pathogens, in Subjects. Patent Application Publication Sep. 29, 2016 Sheet 1 of 23 US 2016/0281166 A1 SSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSSS S{}}\\93? sau36 Patent Application Publication Sep. 29, 2016 Sheet 2 of 23 US 2016/0281166 A1 &**** ? ???zzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzzz??º & %&&zzzzzzzzzzzzzzzzzzzzzzz &Sssssssssssssssssssssssssssssssssssssssssssssssssssssssss & s s sS ------------------------------ Patent Application Publication Sep. 29, 2016 Sheet 3 of 23 US 2016/0281166 A1 23 25 20 FG, 2. Patent Application Publication Sep. 29, 2016 Sheet 4 of 23 US 2016/0281166 A1 : S Patent Application Publication Sep.
    [Show full text]
  • 2012 2013 Causes of Birth Defects: Lessons from History 1 0 Drug
    cited Issue title 2012 2013 Vol.51 NO1 Causes of birth defects: Lessons from history 1 0 (2011) Drug safety in pregnancy: Utopia or achievable prospect? Risk information, risk research and advocacy in Teratology Information 3 0 Services Role of rare cases in deciphering the mechanisms of congenital 2 0 anomalies: CHARGE syndrome research Value of the small cohort study including a physical examination 2 0 for minor structural defects in identifying new human teratogens In vitro models of pancreatic differentiation using embryonic stem 2 1 or induced pluripotent stem cells Peptic ulcer disease with related drug treatment in pregnant 0 0 women and congenital abnormalities in their offspring Efficacy of medical care of epileptic pregnant women based on the 1 0 rate of congenital abnormalities in their offspring Rare clinical entity Perlman syndrome: Is cholestasis a new 0 0 finding? An unusual bronchopulmonary malformation in adulthood: Bronchial 0 0 atresia Vol.51 NO2 Effects of melanocortins on fetal development 0 0 (2011) Hypothyroidism caused by phenobarbital affects patterns of 0 0 estrous cyclicity in rats Adrenocorticotropic tumor cells transplanted into mouse embryos 0 0 affect pancreatic histogenesis Distribution of the longevity gene product, SIRT1, in developing 1 1 mouse organs Is there a reduction of congenital abnormalities in the offspring of diabetic pregnant women after folic acid supplementation? A 3 0 population-based case-control study Analysis of genitourinary anomalies in patients with VACTERL (Vertebral anomalies,
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub
    US 2010O2.10567A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2010/0210567 A1 Bevec (43) Pub. Date: Aug. 19, 2010 (54) USE OF ATUFTSINASATHERAPEUTIC Publication Classification AGENT (51) Int. Cl. A638/07 (2006.01) (76) Inventor: Dorian Bevec, Germering (DE) C07K 5/103 (2006.01) A6IP35/00 (2006.01) Correspondence Address: A6IPL/I6 (2006.01) WINSTEAD PC A6IP3L/20 (2006.01) i. 2O1 US (52) U.S. Cl. ........................................... 514/18: 530/330 9 (US) (57) ABSTRACT (21) Appl. No.: 12/677,311 The present invention is directed to the use of the peptide compound Thr-Lys-Pro-Arg-OH as a therapeutic agent for (22) PCT Filed: Sep. 9, 2008 the prophylaxis and/or treatment of cancer, autoimmune dis eases, fibrotic diseases, inflammatory diseases, neurodegen (86). PCT No.: PCT/EP2008/007470 erative diseases, infectious diseases, lung diseases, heart and vascular diseases and metabolic diseases. Moreover the S371 (c)(1), present invention relates to pharmaceutical compositions (2), (4) Date: Mar. 10, 2010 preferably inform of a lyophilisate or liquid buffersolution or artificial mother milk formulation or mother milk substitute (30) Foreign Application Priority Data containing the peptide Thr-Lys-Pro-Arg-OH optionally together with at least one pharmaceutically acceptable car Sep. 11, 2007 (EP) .................................. O7017754.8 rier, cryoprotectant, lyoprotectant, excipient and/or diluent. US 2010/0210567 A1 Aug. 19, 2010 USE OF ATUFTSNASATHERAPEUTIC ment of Hepatitis BVirus infection, diseases caused by Hepa AGENT titis B Virus infection, acute hepatitis, chronic hepatitis, full minant liver failure, liver cirrhosis, cancer associated with Hepatitis B Virus infection. 0001. The present invention is directed to the use of the Cancer, Tumors, Proliferative Diseases, Malignancies and peptide compound Thr-Lys-Pro-Arg-OH (Tuftsin) as a thera their Metastases peutic agent for the prophylaxis and/or treatment of cancer, 0008.
    [Show full text]
  • Tumor in Patients with 9Q22.3 Microdeletion Syndrome Suggests a Role for PTCH1 in Nephroblastomas
    European Journal of Human Genetics (2013) 21, 784–787 & 2013 Macmillan Publishers Limited All rights reserved 1018-4813/13 www.nature.com/ejhg SHORT REPORT Wilms’ tumor in patients with 9q22.3 microdeletion syndrome suggests a role for PTCH1 in nephroblastomas Bertrand Isidor*,1,2,14, Franck Bourdeaut3,4,5,14, Delfine Lafon6, Ghislaine Plessis7, Elodie Lacaze7, Caroline Kannengiesser8, Sylvie Rossignol9, Olivier Pichon1, Annaig Briand1, Dominique Martin-Coignard10, Maria Piccione11, Albert David1, Olivier Delattre2,Ce´cile Jeanpierre12, Nicolas Se´venet6 and Ce´dric Le Caignec1,13 Nephroblastoma (Wilms’ tumor; WT) is the most common renal tumor of childhood. To date, several genetic abnormalities predisposing to WT have been identified in rare overgrowth syndromes. Among them, abnormal methylation of the 11p15 region, GPC3 and DIS3L2 mutations, which are responsible for Beckwith–Wiedemann, Simpson–Golabi–Behmel and Perlman syndromes, respectively. However, the underlying cause of WT remains unknown in the majority of cases. We report three unrelated patients who presented with WT in addition to a constitutional 9q22.3 microdeletion and dysmorphic/overgrowth syndrome. The size of the deletions was variable (ie, from 1.7 to 8.9 Mb) but invariably encompassed the PTCH1 gene. Subsequently, we identified a somatic PTCH1 nonsense mutation in the renal tumor of one patient. In addition, by array comparative genomic hybridization method, we analyzed the DNA extracted from the blood samples of nine patients with overgrowth syndrome and WT, but did not identify any deleterious chromosomal imbalances in these patients. These findings strongly suggest that patients with constitutional 9q22.3 microdeletion have an increased risk of WT, and that PTCH1 have a role in the pathogenesis of nephroblastomas.
    [Show full text]
  • Beckwith-Wiedemann Syndrome
    560 Med Genet 1994;31:560-564 Syndrome of the month J Med Genet: first published as 10.1136/jmg.31.7.560 on 1 July 1994. Downloaded from Beckwith-Wiedemann syndrome Margaret Elliott, Eamonn R Maher In 1963 Beckwith' presented the necropsy find- features are most apparent before the age of 3 ings of three unrelated children with exompha- years, and after the age of 5 years there is often los, macroglossia, hyperplasia of the kidneys only minor dysmorphism. It is helpful to con- and pancreas, and adrenal cytomegaly, and sug- sider the complications of BWS by the age at gested that this might represent a new syn- presentation. drome. In 1964 Wiedemann2 published a case report of three sibs with exomphalos, macrog- lossia, and overgrowth. Subsequently more PRENATAL than 300 cases have been reported and the Exomphalos complicates approximately half incidence of Beckwith-Wiedemann syndrome the cases of BWS and will usually be picked up (BWS) has been estimated at 007 per 1000 on prenatal ultrasonography, but BWS is a births.34 rare cause of exomphalos (< 3% of all cases).6 Prenatal diagnosis of BWS has occasionally been reported after ultrasonographic detection Clinical features and natural history of a combination of abdominal wall defect, The clinical features of BWS are listed in the polyhydramnios, nephromegaly, and macro- table which is derived from the personal experi- glossia.7 BWS pregnancies are frequently com- ence of one of the authors (ME) of 69 cases in plicated by premature onset of labour. The risk the UK and 22 cases from the one other large of prematurity is associated with an increased clinical study published.5 Anterior abdominal incidence of polyhydramnios but not with fetal wall defects, macroglossia, pre- or postnatal overgrowth alone.
    [Show full text]
  • Cancer Prone Disease Section Mini Review
    Atlas of Genetics and Cytogenetics in Oncology and Haematology OPEN ACCESS JOURNAL AT INIST-CNRS Cancer Prone Disease Section Mini Review Perlman syndrome (renal hamartomas, nephroblastomatosis and fetal gigantism) Maria Piccione, Giovanni Corsello Dipartimento Materno-Infantile University of Palermo, Palermo, Italy Published in Atlas Database: December 2006 Online updated version: http://AtlasGeneticsOncology.org/Kprones/PerlmanID10117.html DOI: 10.4267/2042/38420 This work is licensed under a Creative Commons Attribution-Non-commercial-No Derivative Works 2.0 France Licence. © 2007 Atlas of Genetics and Cytogenetics in Oncology and Haematology Etiology: The genetic basis of the Perlman syndrome is Identity unknown and there is no conclusive laboratory test to Note: The Perlman syndrome is characterized by confirm the diagnosis. Although both sexes are polyhydramnios, fetal overgrowth, neonatal affected, the sex ratio is 2M:1F. The diagnosis is based macrosomia, high neonatal mortality, macrocephaly, on characteristic features and confirmed by histological dysmorphic facial features, visceromegaly, renal evidence. The syndrome has been described in nephroblastomatosis and a predisposition for Wilms both consanguineous and non-consanguineous tumor at very early age. couplings. Inheritance: Inheritance is of an autosomal recessive nature. Figure 1,2 : Macrocephaly, hypertelorism, epicanthus, broad flat nasal bridge, anteverted upper lip, axial hypotonia. Atlas Genet Cytogenet Oncol Haematol. 2007;11(2) 136 Perlman syndrome (renal hamartomas, nephroblastomatosis and fetal gigantism) Piccione M, Corsello G Figure 3 : Abdominal ultrasound scan at 6 months of age: nephromegaly with lobulated contoured kidneys and loss of corticomedullary differentiation. - Cardiomegaly. Clinics - Congenital heart disease: interrupted aortic arch and Phenotype and clinics anomalous coronary vessels and the dextroposition of the heart, muscular ventricular septal defect.
    [Show full text]
  • Syndromes and Constitutional Chromosomal Abnormalities
    Downloaded from jmg.bmj.com on May 16, 2013 - Published by group.bmj.com 705 REVIEW Syndromes and constitutional chromosomal abnormalities associated This article is available free on JMG online via the JMG Unlocked open access trial, with Wilms tumour funded by the Joint Information Systems Committee. For further information, see R H Scott, C A Stiller, L Walker, N Rahman http://jmg.bmjjournals.com/cgi/content/ full/42/2/97 ............................................................................................................................... J Med Genet 2006;43:705–715. doi: 10.1136/jmg.2006.041723 Wilms tumour has been reported in association with over Multiple nephrogenic rests throughout the kid- ney are sometimes present and can be referred to 50 different clinical conditions and several abnormal as nephroblastomatosis. constitutional karyotypes. Conclusive evidence of an The dramatic advances in the treatment of increased risk of Wilms tumour exists for only a minority of Wilms tumour are such that long term survival is now the norm: exceeding 90% for disease these conditions, including WT1 associated syndromes, localised to the abdomen (stages 1–3), and over familial Wilms tumour, and certain overgrowth conditions 70% in metastatic disease (stage 4).7 The treat- such as Beckwith-Wiedemann syndrome. In many reported ment of Wilms tumour is determined both by stage and histological classification of the conditions the rare co-occurrence of Wilms tumour is tumour, with treatment protocols varying probably due to chance. However, for several conditions between countries. Surgical resection is comple- the available evidence cannot either confirm or exclude an mented in the majority of individuals by chemo- therapy. Currently in the United Kingdom increased risk, usually because of the rarity of the around 30% of individuals with Wilms tumour syndrome.
    [Show full text]
  • Differential Diagnoses of Overgrowth Syndromes: the Most Important Clinical and Radiological Disease Manifestations
    Hindawi Publishing Corporation Radiology Research and Practice Volume 2014, Article ID 947451, 7 pages http://dx.doi.org/10.1155/2014/947451 Review Article Differential Diagnoses of Overgrowth Syndromes: The Most Important Clinical and Radiological Disease Manifestations Letícia da Silva Lacerda,1 Úrsula David Alves,1 José Fernando Cardona Zanier,1 Dequitier Carvalho Machado,1,2 Gustavo Bittencourt Camilo,1,2 and Agnaldo José Lopes2 1 Department of Radiology, State University of Rio de Janeiro, 20551-030 Rio de Janeiro, RJ, Brazil 2 Postgraduate Programme in Medical Sciences, State University of Rio de Janeiro, 20550-170 Rio de Janeiro, RJ, Brazil Correspondence should be addressed to Agnaldo Jose´ Lopes; [email protected] Received 12 March 2014; Revised 19 May 2014; Accepted 27 May 2014; Published 9 June 2014 Academic Editor: Andreas H. Mahnken Copyright © 2014 Let´ıcia da Silva Lacerda et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Overgrowth syndromes comprise a heterogeneous group of diseases that are characterized by excessive tissue development. Some of these syndromes may be associated with dysfunction in the receptor tyrosine kinase (RTK)/PI3K/AKT pathway, which results in an increased expression of the insulin receptor. In the current review, four overgrowth syndromes were characterized (Proteus syndrome, Klippel-Trenaunay-Weber syndrome, Madelung’s disease, and neurofibromatosis type I) and illustrated using cases from our institution. Because these syndromes have overlapping clinical manifestations and have no established genetic tests for their diagnosis, radiological methods are important contributors to the diagnosis of many of these syndromes.
    [Show full text]